Multi-billion dollar Operation Warp Speed successor on the way

12 April 2023
hhs_health_human_services_usa_large

A US program worth at least $5 billion is on its way to power development of new COVID-19 vaccines and treatments.

Acting as the successor to Operation Warp Speed, Project Next Gen will help to protect Americans against the mutating virus and other coronavirus threats in the future, according to a report in The Washington Post.

The report states that the program will take a similar approach to Operation Warp Speed, partnering with drugmakers to expedite development of vaccines and therapies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical